Dermata Therapeutics, Inc. (DRMA) Form 10-Q — May 13, 2026
Dermata Therapeutics, Inc. reported a net loss of $1.85 million for the three months ended March 31, 2026, with a net loss per share of $0.48. The company's cash position as of March 31, 2026, was $6.95 million, down from $7.52 million at the end of 2025. The company has a total of 4,022,143 shares of Common Stock issued and outstanding as of March 31, 2026.
Key figures
- Eps
- -0.48
- Net Loss
- 1,847,706
- Total Debt
- 1,052,649
- Cash Position
- 6,945,282
- Shares Outstanding
- 4,022,143
- Reverse split ratio
- 1:10
Price after filing
1 day: +3.4%7 days: +5.0%30 days: +2.5%
Close on the filing date to close N calendar days later (from $1.19). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.